Published in Pharma Investments, Ventures and Law Weekly, November 6th, 2005
In this multicenter, randomized, double-blind, parallel group trial, the safety and efficacy of oxymorphone ER were compared with placebo in 142 opioid-experienced patients with moderate-to-severe chronic low back pain.
Endo said that oxymorphone ER demonstrated a statistically significant difference in pain scores from placebo during a 12-week treatment period,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly